Impact of simultaneous motor-cognitive training on motor capacities in older adults: A quasi-randomized parallel controlled trial.

Exp GerontolJul 1, 2026 (epub)
Clinical ResearchGeriatricsPhysical Medicine & Rehabilitation

Julien Godard, Anna Huet, Manon Rozec et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial evaluated the effects of two types of simultaneous motor-cognitive training on motor capacities in 55 older adults over eight weeks. Results indicated that while training improved motor capacities (p < 0.01), there were no significant differences between the effects of motor-cognitive training and conventional motor training (p > 0.05).

Key findings

  • Training improved motor capacities with a significant effect (p < 0.01; η p 2 [0.14-0.51]).
  • No significant differences were found between incorporated and additional motor-cognitive training modalities (p > 0.05).
  • Motor-cognitive training effects were not different from conventional motor training effects.

Why it matters

Understanding the effectiveness of combined motor-cognitive training can help clinicians design better rehabilitation programs for older adults, potentially enhancing their functional capacities and quality of life.

Source

PubMed · PMID 42385988

Published in Exp Gerontol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Geriatrics

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.